Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis

Annals of Oncology

Volumn 23, Issue 4, 2012, Pages 1030-1036

  Fasol, U ^a   Frost, A ^b   Buchert M ^a   Arends, J ^b   Fiedler, U ^c   Scharr, D ^b   Scheuenpflug, J ^d   Mross, K ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c PROQINASE GMBH   (Germany)

^d AiCuris GmbH   (Germany)

Author keywords

Angiogenesis; Contrast enhanced ultrasound (CEUS); DCE MRI; EndoTAG 1; Liver metastasis; Pharmacokinetic profile

Indexed keywords

ANGIOPOIETIN 2; ENDOTHELIN 1; INTERLEUKIN 6; INTERLEUKIN 8; LIPOSOME; PACLITAXEL; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD FLOW; BLOOD SAMPLING; BONE PAIN; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONSTIPATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; DYSPNEA; ECHOGRAPHY; EPISTAXIS; FATIGUE; FEMALE; FEVER; FLOW RATE; HEADACHE; HUMAN; HYPERHIDROSIS; INTERMETHOD COMPARISON; LIPOSOMAL DELIVERY; LIVER METASTASIS; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; REPEATED DRUG DOSE; REVERSED PHASE LIQUID CHROMATOGRAPHY; SINGLE DRUG DOSE; SYNDROME DELINEATION; TANDEM MASS SPECTROMETRY; TREND STUDY; TUMOR VASCULARIZATION;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANGIOTENSIN II; AREA UNDER CURVE; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; CONTRAST MEDIA; ENDOTHELIN-1; FEMALE; HUMANS; INTERLEUKINS; LIPOSOMES; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PACLITAXEL; PANCREATIC NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84859487837     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr300     Document Type: Article

References (32)

1. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407; 249-257.
2. Kerbel RS, Klement G, Pritchard KI, Kamen B. Continuous low-dose antiangiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 2002; 13: 12-15.
3. Campbell RB, Ying B, Kuesters GM, Hemphill R. Fighting cancer: from the bench to bedside using second generation cationic liposomal therapeutics. J Pharm Sci 2009; 98: 411-429.
4. Strieth S, Eichhorn ME, Sauer B et al. Neovascular targeting chemotherapy: encapsulation of paclitaxel in cationic liposomes impairs functional tumor microvasculature. Int J Cancer 2004; 110: 117-124.
5. Strieth S, Nussbaum CF, Eichhorn ME et al. Tumor-selective vessel occlusions by platelets after vascular targeting chemotherapy using paclitaxel encapsulated in cationic liposomes. Int J Cancer 2008; 122: 452-460.
6. Kunstfeld R, Wickenhauser G, Michaelis U et al. Paclitaxel encapsulated in cationic liposomes diminishes tumor angiogenesis and melanoma growth in a "humanized" SCID mouse model. J Invest Dermatol 2003; 120: 476-482.
7. Schmitt-Sody M, Strieth S, Krasnici S et al. Neovascular targeting therapy: paclitaxel encapsulated in cationic liposomes improves antitumoral efficacy. Clin Cancer Res 2003; 9: 2335-2341.
8. Hylton N. Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker. J Clin Oncol 2006; 24: 3293-3298.
9. Goh V, Padhani AR, Rasheed S. Functional imaging of colorectal cancer angiogenesis. Lancet Oncol 2007; 8: 245-255.
10. O'Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007; 96: 189-195.
11. Mross K, Drevs J, Muller M et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 2005; 41: 1291-1299.
12. Mross K, Stefanic M, Gmehling D et al. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin Cancer Res. 2009; 16: 311-319.
13. Wedam SB, Low JA, Yang SX et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24: 769-777.
14. Drevs J, Siegert P, Medinger M et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol 2007; 25: 3045-3054.
15. Mross K, Fasol U, Frost A et al. DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. J Angiogenes Res 2009; 1: 5.
16. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
17. Scheffler K. On the transient phase of balanced SSFP sequences. Magn Reson Med 2003; 49: 781-783.
18. Rohrer M, Bauer H, Mintorovitch J et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol 2005; 40: 715-724.
19. Tofts PS, Brix G, Buckley DL et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10: 223-232.
20. Evelhoch JL, LoRusso PM, He Z et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vasculartargeting agent ZD6126. Clin Cancer Res 2004; 10: 3650-3657.
21. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997; 7: 91-101.
22. Wei K, Jayaweera AR, Firoozan S et al. Quantification of myocardial blood flow with ultrasound-induced destruction of microbubbles administered as a constant venous infusion. Circulation 1998; 97: 473-483.
23. Eichhorn ME, Becker S, Strieth S et al. Paclitaxel encapsulated in cationic lipid complexes (MBT-0206) impairs functional tumor vascular properties as detected by dynamic contrast enhanced magnetic resonance imaging. Cancer Biol Ther 2006; 5: 89-96.
24. Strieth S, Eichhorn ME, Werner A et al. Paclitaxel encapsulated in cationic liposomes increases tumor microvessel leakiness and improves therapeutic efficacy in combination with cisplatin. Clin Cancer Res 2008; 14: 4603-4611.
25. Löhr M, Haas S, Bechstein W et al. First-line treatment in inoperable pancreatic adenocarcinoma with lipid complexed paclitaxel nanoparticles plus gemcitabine compared with gemcitabine monotherapy. A prospective RCT phase II study. J Clin Oncol 2008; 26: 4618.
26. Liu G, Rugo HS, Wilding G et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005; 23: 5464-5473.
27. Drevs J, Zirrgiebel U, Schmidt-Gersbach CI et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 2005; 16: 558-565.
28. Desar IM, van Herpen CM, van Laarhoven HW et al. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev 2009; 35: 309-321.
29. Azad NS, Annunziata C, Barrett T et al. Dual targeting of vascular endothelial growth factor (VEGF) with sorafenib and bevacizumab: clinical and translational results. J Clin Oncol 2007; 25: 3542.
30. Peterson AC, Swiger S, Stadler WM et al. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res 2004; 10: 4048-4054.
31. Yankeelov TE, Niermann KJ, Huamani J et al. Correlation between estimates of tumor perfusion from microbubble contrast-enhanced sonography and dynamic contrast-enhanced magnetic resonance imaging. J Ultrasound Med 2006; 25: 487-497.
32. Lamuraglia M, Bridal SL, Santin M et al. Clinical relevance of contrast-enhanced ultrasound in monitoring anti-angiogenic therapy of cancer: current status and perspectives. Crit Rev Oncol Hematol 2010; 73: 202-212.